The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds
Yahira M Báez-Santos, Sarah E St John, Andrew D Mesecar, Yahira M Báez-Santos, Sarah E St John, Andrew D Mesecar
Abstract
Over 10 years have passed since the deadly human coronavirus that causes severe acute respiratory syndrome (SARS-CoV) emerged from the Guangdong Province of China. Despite the fact that the SARS-CoV pandemic infected over 8500 individuals, claimed over 800 lives and cost billions of dollars in economic loss worldwide, there still are no clinically approved antiviral drugs, vaccines or monoclonal antibody therapies to treat SARS-CoV infections. The recent emergence of the deadly human coronavirus that causes Middle East respiratory syndrome (MERS-CoV) is a sobering reminder that new and deadly coronaviruses can emerge at any time with the potential to become pandemics. Therefore, the continued development of therapeutic and prophylactic countermeasures to potentially deadly coronaviruses is warranted. The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication. Although the primary function of PLpro and 3CLpro are to process the viral polyprotein in a coordinated manner, PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Therefore, targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells. This review provides an up-to-date discussion on the SARS-CoV papain-like protease including a brief overview of the SARS-CoV genome and replication followed by a more in-depth discussion on the structure and catalytic mechanism of SARS-CoV PLpro, the multiple cellular functions of SARS-CoV PLpro, the inhibition of SARS-CoV PLpro by small molecule inhibitors, and the prospect of inhibiting papain-like protease from other coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses."
Keywords: 3C-like protease; MERS-CoV; Nsp3; Papain-like protease; SARS-CoV; Ubiquitin.
Copyright © 2014 Elsevier B.V. All rights reserved.
Figures
References
- Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4 and 6 induce double-membrane vesicles. MBio. 2013;4
- Baez-Santos Y.M. University of Illinois; Chicago: 2012. Insight into the Substrate Specificity and Inhibition of Human Coronavirus Papain-Like Proteases, Pharmacy. pp. 1–230.
- Baez-Santos Y.M., Barraza S.J., Wilson M.W., Agius M.P., Mielech A.M., Davis N.M., Baker S.C., Larsen S.D., Mesecar A.D. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J. Med. Chem. 2014;57:2393–2412.
- Baez-Santos Y.M., Mielech A.M., Deng X., Baker S., Mesecar A.D. Catalytic function and substrate specificity of the PLpro domain of nsp3 from the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) J. Virol. 2014
- Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. third ed. vol. 1. Elsevier Science; 2012. (Catalytic Mechanisms of Cysteine Peptidases). (chapter 404)
- Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 2005;79:15189–15198.
- Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C. Deubiquitinating activity of the SARS-CoV papain-like protease. Adv. Exp. Med. Biol. 2006;581:37–41.
- Borodovsky A., Kessler B.M., Casagrande R., Overkleeft H.S., Wilkinson K.D., Ploegh H.L. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J. 2001;20:5187–5196.
- Borodovsky A., Ovaa H., Kolli N., Gan-Erdene T., Wilkinson K.D., Ploegh H.L., Kessler B.M. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 2002;9:1149–1159.
- Bredenbeek P.J., Pachuk C.J., Noten A.F., Charite J., Luytjes W., Weiss S.R., Spaan W.J. The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59: a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism. Nucleic Acids Res. 1990;18:1825–1832.
- Brian D.A., Baric R.S. Coronavirus genome structure and replication. Curr. Top. Microbiol. Immunol. 2005;287:1–30.
- Calistri A., Munegato D., Carli I., Parolin C., Palu G. The ubiquitin-conjugating system: multiple roles in viral replication and infection. Cells. 2014;3:386–417.
- Chatterjee A., Johnson M.A., Serrano P., Pedrini B., Joseph J.S., Neuman B.W., Saikatendu K., Buchmeier M.J., Kuhn P., Wuthrich K. Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold. J. Virol. 2009;83:1823–1836.
- Chen X., Chou C.Y., Chang G.G. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir. Chem. Chemother. 2009;19:151–156.
- Cho J.K., Curtis-Long M.J., Lee K.H., Kim D.W., Ryu H.W., Yuk H.J., Park K.H. Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa. Bioorg. Med. Chem. 2013;21:3051–3057.
- Chou C.Y., Chien C.H., Han Y.S., Prebanda M.T., Hsieh H.P., Turk B., Chang G.G., Chen X. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem. Pharmacol. 2008;75:1601–1609.
- Chou C.Y., Lai H.Y., Chen H.Y., Cheng S.C., Cheng K.W., Chou Y.W. Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease. Acta Crystallogr. D Biol. Crystallogr. 2014;70:572–581.
- Chouljenko V.N., Lin X.Q., Storz J., Kousoulas K.G., Gorbalenya A.E. Comparison of genomic and predicted amino acid sequences of respiratory and enteric bovine coronaviruses isolated from the same animal with fatal shipping pneumonia. J. Gen. Virol. 2001;82:2927–2933.
- Clementz M.A., Chen Z., Banach B.S., Wang Y., Sun L., Ratia K., Baez-Santos Y.M., Wang J., Takayama J., Ghosh A.K., Li K., Mesecar A.D., Baker S.C. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J. Virol. 2010;84:4619–4629.
- Devaraj S.G., Wang N., Chen Z., Tseng M., Barretto N., Lin R., Peters C.J., Tseng C.T., Baker S.C., Li K. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 2007;282:32208–32221.
- Egloff M.P., Malet H., Putics A., Heinonen M., Dutartre H., Frangeul A., Gruez A., Campanacci V., Cambillau C., Ziebuhr J., Ahola T., Canard B. Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains. J. Virol. 2006;80:8493–8502.
- Fraile J.M., Quesada V., Rodriguez D., Freije J.M., Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31:2373–2388.
- Frieman M., Basu D., Matthews K., Taylor J., Jones G., Pickles R., Baric R., Engel D.A. Yeast based small molecule screen for inhibitors of SARS-CoV. PLoS One. 2011;6:e28479.
- Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 2009;83:6689–6705.
- Ghosh A.K., Takayama J., Aubin Y., Ratia K., Chaudhuri R., Baez Y., Sleeman K., Coughlin M., Nichols D.B., Mulhearn D.C., Prabhakar B.S., Baker S.C., Johnson M.E., Mesecar A.D. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. J. Med. Chem. 2009;52:5228–5240.
- Ghosh A.K., Takayama J., Rao K.V., Ratia K., Chaudhuri R., Mulhearn D.C., Lee H., Nichols D.B., Baliji S., Baker S.C., Johnson M.E., Mesecar A.D. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. J. Med. Chem. 2010;53:4968–4979.
- Ghosh A.K., Xi K., Johnson M.E., Baker S.C., Mesecar A.D. Progress in anti-SARS coronavirus chemistry, biology and chemotherapy. Annu. Rep. Med. Chem. 2006;41:183–196.
- Ghosh A.K., Xi K., Ratia K., Santarsiero B.D., Fu W.T., Harcourt B.H., Rota P.A., Baker S.C., Johnson M.E., Mesecar A.D. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J. Med. Chem. 2005;48:6767–6771.
- Gosert R., Kanjanahaluethai A., Egger D., Bienz K., Baker S.C. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. J. Virol. 2002;76:3697–3708.
- Hagemeijer M.C., Verheije M.H., Ulasli M., Shaltiel I.A., de Vries L.A., Reggiori F., Rottier P.J., de Haan C.A. Dynamics of coronavirus replication-transcription complexes. J. Virol. 2010;84:2134–2149.
- Han Y.S., Chang G.G., Juo C.G., Lee H.J., Yeh S.H., Hsu J.T., Chen X. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry. 2005;44:10349–10359.
- Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J., Severson K.M., Smith C.M., Rota P.A., Baker S.C. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J. Virol. 2004;78:13600–13612.
- Hu M., Li P., Li M., Li W., Yao T., Wu J.W., Gu W., Cohen R.E., Shi Y. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2002;111:1041–1054.
- Imbert I., Snijder E.J., Dimitrova M., Guillemot J.C., Lecine P., Canard B. The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. Virus Res. 2008;133:136–148.
- Jacobs J., Grum-Tokars V., Zhou Y., Turlington M., Saldanha S.A., Chase P., Eggler A., Dawson E.S., Baez-Santos Y.M., Tomar S., Mielech A.M., Baker S.C., Lindsley C.W., Hodder P., Mesecar A., Stauffer S.R. Discovery, synthesis, and structure-based optimization of a series of n-(tert-butyl)-2-(n-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J. Med. Chem. 2013;56:534–546.
- Jain R.P., Pettersson H.I., Zhang J.M., Aull K.D., Fortin P.D., Huitema C., Eltis L.D., Parrish J.C., James M.N.G., Wishart D.S., Vederas J.C. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CL(pro) J. Med. Chem. 2004;47:6113–6116.
- Johnson M.A., Chatterjee A., Neuman B.W., Wuthrich K. SARS coronavirus unique domain: three-domain molecular architecture in solution and RNA binding. J. Mol. Biol. 2010;400:724–742.
- Kanjanahaluethai A., Chen Z., Jukneliene D., Baker S.C. Membrane topology of murine coronavirus replicase nonstructural protein 3. Virology. 2007;361:391–401.
- Knoops K., Kikkert M., Worm S.H., Zevenhoven-Dobbe J.C., van der Meer Y., Koster A.J., Mommaas A.M., Snijder E.J. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6:e226.
- Lei J., Mesters J.R., Drosten C., Anemuller S., Ma Q., Hilgenfeld R. Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. Antiviral Res. 2014;109:72–82.
- Lindner H.A., Fotouhi-Ardakani N., Lytvyn V., Lachance P., Sulea T., Menard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. 2005;79:15199–15208.
- Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch. Biochem. Biophys. 2007;466:8–14.
- Love K.R., Catic A., Schlieker C., Ploegh H.L. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat. Chem. Biol. 2007;3:697–705.
- McNaught A.D., Wilkinson A. second ed. IUPAC; 1997. Compendium of Chemical Terminology. (the “Gold Book”)
- Melandri F., Grenier L., Plamondon L., Huskey W.P., Stein R.L. Kinetic studies on the inhibition of isopeptidase T by ubiquitin aldehyde. Biochemistry. 1996;35:12893–12900.
- Mielech A.M., Chen Y., Mesecar A.D., Baker S.C. Nidovirus papain-like proteases: Multifunctional enzymes with protease, deubiquitinating and deISGylating activities. Virus Res. 2014
- Mielech A.M., Kilianski A., Baez-Santos Y.M., Mesecar A.D., Baker S.C. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology. 2014;450–451:64–70.
- Molland K., Zhou Q., Mesecar A.D. A 2.2 Å resolution structure of the USP7 catalytic domain in a new space group elaborates upon structural rearrangements resulting from ubiquitin binding. Acta Crystallogr. F Struct. Biol. Commun. 2014;70:283–287.
- Neuman B.W., Joseph J.S., Saikatendu K.S., Serrano P., Chatterjee A., Johnson M.A., Liao L., Klaus J.P., Yates J.R., 3rd, Wuthrich K., Stevens R.C., Buchmeier M.J., Kuhn P. Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J. Virol. 2008;82:5279–5294.
- Nicholson B., Leach C.A., Goldenberg S.J., Francis D.M., Kodrasov M.P., Tian X., Shanks J., Sterner D.E., Bernal A., Mattern M.R., Wilkinson K.D., Butt T.R. Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci. 2008;17:1035–1043.
- Oostra M., Hagemeijer M.C., van Gent M., Bekker C.P., te Lintelo E.G., Rottier P.J., de Haan C.A. Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning. J. Virol. 2008;82:12392–12405.
- Oostra M., te Lintelo E.G., Deijs M., Verheije M.H., Rottier P.J., de Haan C.A. Localization and membrane topology of coronavirus nonstructural protein 4: involvement of the early secretory pathway in replication. J. Virol. 2007;81:12323–12336.
- Park J.Y., Jeong H.J., Kim J.H., Kim Y.M., Park S.J., Kim D., Park K.H., Lee W.S., Ryu Y.B. Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biol. Pharm. Bull. 2012;35:2036–2042.
- Park J.Y., Kim J.H., Kim Y.M., Jeong H.J., Kim D.W., Park K.H., Kwon H.J., Park S.J., Lee W.S., Ryu Y.B. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg. Med. Chem. 2012;20:5928–5935.
- Ratia K., Kilianski A., Baez-Santos Y.M., Baker S.C., Mesecar A.D. Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease. PLoS Pathog. 2014;10:e1004113.
- Ratia K., Pegan S., Takayama J., Sleeman K., Coughlin M., Baliji S., Chaudhuri R., Fu W., Prabhakar B.S., Johnson M.E., Baker S.C., Ghosh A.K., Mesecar A.D. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. U.S.A. 2008;105:16119–16124.
- Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C., Stevens R.C., Mesecar A.D. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl. Acad. Sci. U.S.A. 2006;103:5717–5722.
- Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M., Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P. Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1″-phosphate dephosphorylation by a conserved domain of nsP3. Structure (Camb) 2005;13:1665–1675.
- Serrano P., Johnson M.A., Almeida M.S., Horst R., Herrmann T., Joseph J.S., Neuman B.W., Subramanian V., Saikatendu K.S., Buchmeier M.J., Stevens R.C., Kuhn P., Wuthrich K. Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:12049–12060.
- Serrano P., Johnson M.A., Chatterjee A., Neuman B.W., Joseph J.S., Buchmeier M.J., Kuhn P., Wuthrich K. Nuclear magnetic resonance structure of the nucleic acid-binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3. J. Virol. 2009;83:12998–13008.
- Snijder E.J., Bredenbeek P.J., Dobbe J.C., Thiel V., Ziebuhr J., Poon L.L., Guan Y., Rozanov M., Spaan W.J., Gorbalenya A.E. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 2003;331:991–1004.
- Sun L., Xing Y., Chen X., Zheng Y., Yang Y., Nichols D.B., Clementz M.A., Banach B.S., Li K., Baker S.C., Chen Z. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012;7:e30802.
- Tan J., Kusov Y., Mutschall D., Tech S., Nagarajan K., Hilgenfeld R., Schmidt C.L. The “SARS-unique domain” (SUD) of SARS coronavirus is an oligo(G)-binding protein. Biochem. Biophys. Res. Commun. 2007;364:877–882.
- Tan J., Vonrhein C., Smart O.S., Bricogne G., Bollati M., Kusov Y., Hansen G., Mesters J.R., Schmidt C.L., Hilgenfeld R. The SARS-unique domain (SUD) of SARS coronavirus contains two macrodomains that bind G-quadruplexes. PLoS Pathog. 2009;5:e1000428.
- Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E., Ziebuhr J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 2003;84:2305–2315.
- Tong T.R. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Infect. Disord. Drug Targets. 2009;9:223–245.
- van Hemert M.J., van den Worm S.H., Knoops K., Mommaas A.M., Gorbalenya A.E., Snijder E.J. SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog. 2008;4:e1000054.
- Wilkinson K.D., Gan-Erdene T., Kolli N. Derivitization of the C-terminus of ubiquitin and ubiquitin-like proteins using intein chemistry: methods and uses. Methods Enzymol. 2005;399:37–51.
- Xue X.Y., Yu H.W., Yang H.T., Xue F., Wu Z.X., Shen W., Li J., Zhou Z., Ding Y., Zhao Q., Zhang X.J.C., Liao M., Bartlam M., Rao Z. Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design. J. Virol. 2008;82:2515–2527.
- Yang S., Chen S.J., Hsu M.F., Wu J.D., Tseng C.T.K., Liu Y.F., Chen H.C., Kuo C.W., Wu C.S., Chang L.W., Chen W.C., Liao S.Y., Chang T.Y., Hung H.H., Shr H.L., Liu C.Y., Huang Y.A., Chang L.Y., Hsu J.C., Peters C.J., Wang A.H.J., Hsu M.C. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J. Med. Chem. 2006;49:4971–4980.
- Zhang J.M., Pettersson H.I., Huitema C., Niu C.Y., Yin J., James M.N.G., Eltis L.D., Vederas J.C. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters. J. Med. Chem. 2007;50:1850–1864.
- Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr. Opin. Microbiol. 2004;7:412–419.
- Ziebuhr J., Snijder E.J., Gorbalenya A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 2000;81:853–879.
- Ziebuhr J., Thiel V., Gorbalenya A.E. The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond. J. Biol. Chem. 2001;276:33220–33232.
Source: PubMed